Homestead Advisers Corp Sells 8,200 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Homestead Advisers Corp reduced its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 40.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 12,250 shares of the company’s stock after selling 8,200 shares during the period. Homestead Advisers Corp’s holdings in Medpace were worth $4,070,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of MEDP. Vanguard Group Inc. boosted its stake in Medpace by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 2,570,770 shares of the company’s stock valued at $854,087,000 after acquiring an additional 25,704 shares in the last quarter. State Street Corp increased its position in shares of Medpace by 7.2% during the third quarter. State Street Corp now owns 752,957 shares of the company’s stock worth $251,337,000 after purchasing an additional 50,312 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Medpace by 7.6% during the 3rd quarter. Geode Capital Management LLC now owns 628,054 shares of the company’s stock valued at $209,885,000 after purchasing an additional 44,371 shares during the last quarter. Wellington Management Group LLP grew its stake in Medpace by 36.0% during the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock worth $138,612,000 after buying an additional 109,886 shares during the last quarter. Finally, American Capital Management Inc. grew its stake in Medpace by 2.6% during the 3rd quarter. American Capital Management Inc. now owns 380,646 shares of the company’s stock worth $127,060,000 after buying an additional 9,592 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of MEDP opened at $317.65 on Thursday. Medpace Holdings, Inc. has a fifty-two week low of $302.01 and a fifty-two week high of $459.77. The company has a market capitalization of $9.68 billion, a P/E ratio of 25.15, a P/E/G ratio of 3.81 and a beta of 1.47. The business’s 50-day moving average is $336.81 and its two-hundred day moving average is $339.41.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on MEDP shares. Robert W. Baird raised their price target on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Leerink Partners assumed coverage on shares of Medpace in a research report on Monday. They set a “market perform” rating and a $330.00 target price on the stock. Finally, Leerink Partnrs raised shares of Medpace to a “hold” rating in a report on Monday. Nine investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Medpace presently has a consensus rating of “Hold” and an average target price of $376.30.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.